[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Matsumura K, Sugimura K, Uchida J, Naganuma T, Nakatani T: Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy. Int J Urol; 2003 Feb;10(2):105-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy.
  • We report a case of advanced ureteral cancer successfully treated with systemic chemotherapy combined with irradiation.
  • A 47-year-old man was diagnosed as having a right ureteral cancer at the clinical stage of T4, N2 and M1 (liver).
  • A papillary tumor was also found in the bladder and the resected specimen showed a grade 1 transitional cell carcinoma.
  • Although three cycles of methotrexate, vinblastine, pirarubicin and cisplatin (MVAC) gave partial response to the ureteral tumor, new metastases to the lung and pelvic bone were observed.
  • The patient received 50 Gy external irradiation to the pelvis, 11 cycles of paclitaxel (270 mg) and cisplatin (60-80 mg) followed by four cycles of docetaxel (100 mg) and cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Methotrexate / administration & dosage. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / radiotherapy. Vinblastine / administration & dosage
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12588609.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


2. Inoue T, Ohyama C, Horikawa Y, Togashi H, Matsuura S, Tsuchiya N, Satoh S, Sato K, Habuchi T, Saito S, Hoshi S, Arai Y, Kato T: [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma]. Hinyokika Kiyo; 2004 Apr;50(4):273-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
  • We report three cases with methotrexate-vinblastin-adriamycin-cisplatin (MVAC) resistant multiple liver metastases of urothelial carcinoma that responded to combination chemotherapy consisting of gemcitabine plus carboplatin (GC) with additional docetaxel (GCD) as salvage chemotherapy.
  • Case 1: A 55-year-old man underwent left nephroureterectomy for ureteral cancer (TCC, G3, pT3pN1M0).
  • Three courses of GC followed by three courses of GCD were given via intra-hepatic arterial infusion for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • Case 2: A 46-year-old man underwent radical cystectomy for locally advanced bladder cancer (TCC G3 + adenocarcinoma. pT3pN0M0).
  • Two courses of GC followed by 2 courses of GCD systemic therapies were performed for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • Case 3: A 66-year-old man received three courses of MVAC for multiple metastases of the bladder cancer (TCC, G3, > pT2), which resulted in disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Taxoids / administration & dosage. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15188623.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


3. Tsukamoto T, Yonese J, Ishii N, Maezawa T, Fukui I: [Successful salvage chemotherapy with gemcitabine, etoposide and cisplatin for metastatic ureteral cancer: a case report]. Hinyokika Kiyo; 2002 Jul;48(7):427-30
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful salvage chemotherapy with gemcitabine, etoposide and cisplatin for metastatic ureteral cancer: a case report].
  • A 35-year-old man who had undergone nephroureterectomy and a single cycle of adjuvant MVAC chemotherapy for the left ureteral cancer was referred our clinic for the treatment of paraaortic lymph node metastases.
  • Following histologic confirmation of transitional cell carcinoma by computed tomography (CT) guided biopsy, we treated him with combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin.
  • After 5 cycles of chemotherapy complete remission was obtained.
  • Thus, we treated him with a new combination chemotherapy comprising gemcitabine, etoposide and cisplatin which was approved as a phase I study by the institutional review board.
  • Adjuvant radiotherapy of 40 Gy was given to the metastatic sites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / therapy. Deoxycytidine / analogs & derivatives. Salvage Therapy. Ureteral Neoplasms / therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Lymphatic Metastasis. Male. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229181.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Takayama T, Nagata M, Unno T, Mugiya S, Hata M, Suzuki K, Fujita K: [A clinical study of patients undergoing curative surgery for renal pelvic and ureteral cancers]. Hinyokika Kiyo; 2000 Mar;46(3):155-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of patients undergoing curative surgery for renal pelvic and ureteral cancers].
  • We retrospectively studied 30 patients who underwent curative surgery for renal pelvic and/or ureteral cancer between August 1987 and August 1998.
  • Nine patients who received adjuvant chemotherapy are alive, but 3 patients have relapsed.
  • Chemotherapy did not have a significant effect on the cause-specific survival or disease-free survival.
  • [MeSH-major] Kidney Neoplasms / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Kidney Pelvis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10806570.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


5. Abe T, Konari S, Ogata M, Komatsu S, Satoh T: [A case of CEA-producing renal pelvic and ureteral cancer]. Hinyokika Kiyo; 2003 Feb;49(2):75-9
Genetic Alliance. consumer health - Kidney cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of CEA-producing renal pelvic and ureteral cancer].
  • We report a case of carcinoembryonic antigen (CEA)-producing renal pelvic and ureteral cancer.
  • On ultrasonography and CT scan, right hydronephrosis with the renal pelvis and ureteral tumor were detected, and he was referred to our hospital.
  • Close examination of the gastro-intestinal tract did not detect any sign of digestive tumor.
  • Right nephro-ureterectomy was performed, and the tumor was histologically diagnosed as TCC G2 > G3 pT3, and CEA was positive in the tumor cells immunohistochemically.
  • CA19-9 was also positive both in the tumor cells and normal epithelium of the renal tubules.
  • Postoperatively, multiple lung metastases developed despite chemotherapy and the patient died 4 months after surgery.
  • CEA had transiently decreased postoperatively, but then increased with lung metastases, apparently related to the state of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoma, Transitional Cell / diagnosis. Kidney Pelvis / immunology. Ureteral Neoplasms / diagnosis
  • [MeSH-minor] CA-19-9 Antigen / blood. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12696186.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 17
  •  go-up   go-down


6. Yasuda Y, Tatokoro M, Yokoyama M, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K: [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation]. Nihon Hinyokika Gakkai Zasshi; 2010 Nov;101(7):758-63
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation].
  • Computed tomography (CT) scan revealed right hydronephrosis and a slightly enhanced invasive tumor in the right lower ureter, providing a diagnosis of ureteral cancer stage cT3NOM0.
  • After three courses of combination chemotherapy consisting of gemcitabine and cisplatin (GC), one tumor completely disappeared and another achieved a partial response.
  • The patient underwent radiofrequency ablation (RFA) for the residual followed by GC chemotherapy.
  • The patient underwent RFA again followed by GC chemotherapy and then all hepatic metastases have not revealed enlargement.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Catheter Ablation. Liver Neoplasms / secondary. Neoplasms, Multiple Primary. Quality of Life. Ureteral Neoplasms / pathology. Ureteral Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lymphatic Metastasis. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174743.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Wang H, Satoh M, Abe H, Sunamura M, Moriya T, Ishidoya S, Saito S, Hamada H, Arai Y: Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. Urology; 2006 Sep;68(3):674-81
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
  • OBJECTIVES: To investigate the therapeutic effect of AxdAdB-3, a double-restricted oncolytic adenovirus harboring a mutant E1A and an E1B-55KD deletion, on human bladder cancer cell lines and the SCID mouse model of orthotopic bladder cancer.
  • METHODS: The cytopathic effects of AxdAdB-3 were evaluated in several cell lines (YTS-1, YTS-3, T24, J82, 5637) derived from human bladder or ureteral cancer and in a normal bladder mucosa-derived cell line (HCV29) with AxCAlacZ (control) or AxE1AdB (E1B-55KD-defective adenovirus) or dl922-947 (E1A-mutated adenovirus).
  • The efficacy of bladder instillation therapy with AxdAdB-3 for orthotopic bladder cancer of SCID mice was investigated.
  • RESULTS: AxdAdB-3 caused the oncolysis of bladder cancer cell lines in vitro, and it was more cytopathic than AxE1AdB or dl922-947 in the cancer cell lines.
  • Direct instillation of AxdAdB-3 into the bladder of the orthotopic model inhibited tumor growth, leading to significantly prolonged survival.
  • CONCLUSIONS: Oncolytic viral therapy delivered by instillation of AxdAdB-3 is a promising tool for treating bladder cancer.
  • [MeSH-major] Adenoviridae / genetics. Oncolytic Virotherapy / methods. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Animals. Cell Line, Tumor. Disease Models, Animal. Humans. Mice. Mice, SCID

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979729.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Bondavalli C, Dall'Oglio B, Schiavon L, Luciano M, Guatelli S, Parma P, Galletta V: [Complications of urinary diversion after radiotherapy]. Arch Ital Urol Androl; 2003 Mar;75(1):10-3
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary radiation therapy may be recommended for patients with invasive bladder cancer, gynecological or prostatic cancer.
  • When complications occur or in case of malignant recurrence, urinary diversion may be the best chance to restore an acceptable quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12741338.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


9. Sagristani M, Caraglia M, Villa MR, Lucania A, Esposito M, Petriccione L, Improta S, Marra M, Iannaci G, Rossiello R, Mastrullo L: Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer. J Exp Clin Cancer Res; 2007 Jun;26(2):291-2
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer.
  • In this manuscript for the first time we describe the concomitant diagnosis of primary renal non-Hodgkin lymphoma (PRL) and of a papillary urothelial cancer in a patient with megaloblastic anemia.
  • PRL is a rare disease, since the kidney is one of the extranodal organs usually not containing lymphoid tissue.
  • A review of literature indicated that simultaneous diagnosis of PRL and papillary urothelial carcinoma of the urether, makes our case unique.
  • The early diagnosis of both diseases allowed the eradication of the two neoplasms by nephro-ureterecthomy and by performing subsequent systemic chemotherapy.
  • [MeSH-major] Carcinoma, Papillary / radiography. Kidney Neoplasms / radiography. Lymphoma, Non-Hodgkin / radiography. Ureteral Neoplasms / radiography
  • [MeSH-minor] Early Diagnosis. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725112.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, Itoh N, Tsukamoto T: Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology; 2000 May;55(5):663-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for the development of bladder cancer after upper tract urothelial cancer.
  • OBJECTIVES: To determine the clinical and pathologic risk factors for initial intravesical recurrence in patients with primary renal pelvic and/or ureteral cancer and to examine the progression in the bladder in patients having high risk factors for intravesical recurrence.
  • METHODS: This study included 69 patients with renal pelvic and/or ureteral cancer.
  • We excluded patients with distant metastases, those with a short period of follow-up, and those having a previous history or concomitance of bladder cancer.
  • The exclusion criteria were chosen to avoid contamination by patients with a poor prognosis who might die of the primary cancer before bladder cancer development.
  • Multivariate analysis by Cox's proportional hazards model was used to determine what clinical and pathologic variables significantly affected the initial intravesical recurrence of cancer.
  • We also studied the stage progression of cancer that recurred in the bladder.
  • RESULTS: Initial intravesical recurrence of the cancer was found in 22 patients during a median follow-up period of 53 months (range 12 to 225).
  • The intravesical disease-free rate after upper tract urothelial cancer was 65% (rate of disease recurrence in bladder 35%) at 5 years by the Kaplan-Meier method.
  • The extent (multifocality) of the upper urinary cancer (P = 0.0038) and pathologic stage (P = 0.0409) independently influenced intravesical recurrence.
  • Age, sex, adjuvant chemotherapy, configuration of the primary tumor, primary cancer size, and pathologic grade did not affect recurrence.
  • CONCLUSIONS: The extent and pathologic stage of cancer in the upper urinary tract were significant and independent factors for initial intravesical recurrence of cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792075.001).
  • [ISSN] 0090-4295
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


11. Watanabe M, Hayashi T, Takamatsu M, Kamitani A, Inoue M, Morisue K, Irie S, Kaneshige T: [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment]. Nihon Hinyokika Gakkai Zasshi; 2003 Mar;94(3):428-33
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment].
  • PURPOSE: A retrospective investigation of patients presenting with renal pelvic and ureteral cancer was performed.
  • This study focused on the prognostic factors and frequency of subsequent bladder cancer following surgical treatment.
  • Various factors were evaluated according to survival and non-bladder cancer occurrence rates.
  • Seventeen patients exhibited renal pelvic cancer, 25 cases displayed ureteral cancer and three subjects presented with multiple cancers.
  • Eleven patients had received treatment for precedent or coexistent superficial bladder cancer by transurethral resection.
  • Pathological T factor, tumor grade and pN factor demonstrated a significant effect on survival; however, sex, age, tumor localization and incidence of subsequent bladder cancer had no influence on survival.
  • The 5-year non-bladder cancer occurrence rate was 38.8%; additionally, all subsequent bladder cancer was disclosed within three years.
  • Tumor multiplicity exclusively in the upper urinary tract significantly affected occurrence of bladder cancer.
  • T factor and tumor grade revealed no correlation to occurrence.
  • CONCLUSIONS: Adjuvant chemotherapy for prevention of clinical metastasis should be considered in cases involving pT3 or higher stage, grade 3, or in instances of pathologically confirmed lymph node metastasis.
  • The significant occurrence of subsequent bladder cancer in the case of tumor multiplicity suggested that prophylactic therapy such as intravesical BCG instillation or chemotherapy might be beneficial.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / etiology

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12710077.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Ishida K, Yuhara K, Kanimoto Y: [Septic shock following intracavitary Bacillus Calmette-Guerin therapy for postcystectomy ureteral cancer]. Hinyokika Kiyo; 2004 Sep;50(9):633-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Septic shock following intracavitary Bacillus Calmette-Guerin therapy for postcystectomy ureteral cancer].
  • A 72-year-old female patient was diagnosed as having a tumor in her bladder at the department of obstetrics and gynecology.
  • Transurethral resection of bladder tumor was performed in November, 2002.
  • Chemotherapy consisting of methotrexate, adriamycin and cisplatin and bladder instillation of Bacillus Calmette-Guerin (BCG) was performed.
  • Re-biopsy revealed transitional cell carcinoma, G2, carcinoma in situ of the bladder and she received radical cystectomy with ureterocutaneostomy in June, 2003.
  • After the cystectomy, the left ureter showed signs of cancer so BCG was administered through the left ureterocutaneostomy.
  • After she was given endotoxin absorption therapy, she regained normal blood pressure and her heart rate, but was still febrile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15518130.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


13. Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG: [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun;31(3):288-91
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation].
  • OBJECTIVE: To investigate the types and therapies of malignancies in renal allograft recipients.
  • METHODS: We retrospectively analyzed the occurrence, types, and therapies of malignancies in 498 renal allograft recipients who had received operations in Peking Union Medical College Hospital from May 1986 to October 2008.
  • RESULTS: Among 498 renal allograft recipients, 18 patients (3.6% ) were diagnosed with malignancies, which included bladder cancer (n = 5), renal pyloric cancer or ureteric cancer (n = 4), leukemia or lymphoma (n = 3), hepatic cancer (n = 2), skin cancer, rectum carcinoma, pulmonary carcinoma and thymoma (n = 1 each).
  • Three patients with bladder cancer and one patient with ureteric cancer experienced recurrences 7 to 15 months after operations; among them one bladder cancer patient died.
  • One non-Hodgkin's lymphoma patient died 11 months after chemotherapy.
  • Five cases with advanced unresectable malignancies died 8 to 17 months after the diagnosis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621511.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Yasuda K, Kawa G, Kinoshita H, Matsuda T: [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here a case of ureteral cancer in which port-site metastasis was suspected after a nephroureterectomy.
  • A tumor was found in his left renal pelvis and ureter by a computed tomographic (CT) scan.
  • The patient was diagnosed with a left upper urinary tract cancer with a clinical stage of T2N0M0.
  • The pathological diagnosis was an urothelial carcinoma, grade 2 > 3, INFbeta, pT3, pV1, pN2.
  • He received two courses of MVAC chemotherapy (methotrexate 50 mg, vinblastine 5 mg, adriamycin 50mg, cisplatin 120 mg) postoperatively.
  • Since retroperitoneal lymph node metastasis was observed three months later on a CT scan, the MVAC chemotherapy was repeated for three courses.
  • Nine months later, a tumor was found in the hypodermic beside the port-site, and a needle biopsy confirmed a metastatic urothelial carcinoma.
  • He received two courses of GP chemotherapy (gemcitabine 4,250 mg, paclitaxel 225 mg).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Laparoscopy. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378825.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


15. Kaneko T, Fujita K, Homma Y: Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer. Int J Urol; 2006 Mar;13(3):294-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer.
  • A 76-year-old man received intravesical bacillus Calmette-Guérin (BCG) instillations for recurrent superficial bladder cancer.
  • He had undergone right nephroureterectomy for right renal pelvic cancer 9 months previously.
  • There was no sign of recurrent bladder cancer or ureteral cancer.
  • Most of the side-effects of intravesical BCG therapy are minor, and major adverse reactions are rare.
  • Life-threatening ureteral obstruction would be a rare complication of BCG immunotherapy.
  • Although BCG intravesical instillation after nephroureterectomy is a common practice, special care should be taken of renal function in patients with unilateral kidney during BCG therapy.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. Anuria / chemically induced. BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / drug therapy. Nephrostomy, Percutaneous. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Time Factors. Tomography, X-Ray Computed. Urography

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643629.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


16. Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I: Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol; 2004 Aug;11(8):592-6
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intravesical oxybutynin chloride with hydroxypropylcellulose (HPC) (modified intravesical oxybutynin) has been reported to be effective for treatment of overactive bladder.
  • METHODS: Modified intravesical oxybutynin (5 mg/10 mL, twice a day) was applied for more than 3 years to six neurogenic overactive detrusor patients (three men and three women, average age 53.3 years) who were not satisfied with oral anticholinergic agents or the other therapy.
  • A cystometogram (CMG) was performed before, 1 week after and 3 years after the start of modified intravesical oxybutynin treatment.
  • We evaluated the patient's satisfaction of this treatment after 4 weeks and again after 3 years.
  • We compared the patients' answers before and after the therapy (excellent, good, fair, unchanged and worse).
  • RESULTS: CMG studies showed that two of six patients no longer exhibited uninhibited contraction 1 week after the treatment and that the cystocapacity of patients before, 1 week after and 3 years after the initial modified intravesical oxybutynin was 129.7 +/- 19.4, 283.5 +/- 40.4 and 286.8 +/- 38.1 mL, respectively.
  • For the evaluation of patients' satisfaction with this treatment, four patients considered the therapy excellent and one patient described it as good after both 4 weeks and after 3 years.
  • Two patients dropped out of the study; one developed left ureteral cancer (2.25 years) and the other developed ileus (1.5 years).
  • CONCLUSION: Modified intravesical oxybutynin is an effective and relatively safe option of therapy for overactive bladder patients.
  • However, this therapy requires careful observation for emergent side-effects.
  • [MeSH-major] Cellulose / administration & dosage. Cellulose / analogs & derivatives. Mandelic Acids / administration & dosage. Urinary Bladder, Neurogenic / drug therapy. Urinary Incontinence / drug therapy. Urodynamics / drug effects
  • [MeSH-minor] Administration, Intravesical. Adolescent. Aged. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Patient Satisfaction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285747.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Mandelic Acids; 9004-34-6 / Cellulose; K9P6MC7092 / oxybutynin; RFW2ET671P / hydroxypropylcellulose
  •  go-up   go-down


17. Parisi S, Troiano M, Corsa P, Raguso A, Cossa S, Piazzolla EE, Munafò T, Sanpaolo G, Natuno A, Maiello E: Role of external radiation therapy in urinary cancers. Ann Oncol; 2007 Jun;18 Suppl 6:vi157-61
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of external radiation therapy in urinary cancers.
  • Invasive urinary tumors are relatively rare and their treatment may cause important changes in urinary, sexual, and social functions.
  • A systematic review of external radiation therapy studies in urinary cancers has been carried out.
  • There are few controlled clinical trials using adjuvant or radical radiotherapy +/- chemotherapy in kidney, ureter, and urethra cancers; there are several reports of muscle-invasive bladder cancer using multimodality treatment: intravesical surgery and neo-adjuvant chemotherapy to radiotherapy or concomitant radiochemotherapy with organ preservation.
  • The conclusions reached for renal cancer are controversial; urethra and ureter cancers data are few and inconclusive; sufficient data now exist in literature to demonstrate that conservative management with organ preservation, for muscle-invasive bladder cancer, is a valid alternative to radical cystectomy, viewed as the gold standard.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591812.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 34
  •  go-up   go-down


18. Mizutani K, Ehara H, Yokoi S, Phuoc NB, Deguchi T, Hirose Y: Treatment-related ureteral cancer following stage II testicular seminoma. Int J Clin Oncol; 2007 Dec;12(6):469-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related ureteral cancer following stage II testicular seminoma.
  • We report two cases of left ureteral carcinoma that may have been related to prior radiotherapy and anticancer chemotherapy for stage II testicular seminoma.
  • Both patients had undergone radiotherapy (60 Gy) and cisplatin-based chemotherapy, one 17 years before the present presentation and the other 24 years earlier.
  • They underwent retroperitoneoscopy-assisted left nephroureterectomy under a diagnosis of left upper ureteral cancer, established by means of ureteroscopy and brush biopsy.
  • Recently, some investigators have reported that testicular cancer survivors are at significantly increased risk of solid tumors for at least 35 years after treatment.
  • Young patients may have a high risk of cancer when they reach an advanced age.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neoplasms, Second Primary. Radiotherapy / adverse effects. Seminoma. Testicular Neoplasms. Ureteral Neoplasms / etiology
  • [MeSH-minor] Cisplatin / adverse effects. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):640-7 [14726503.001]
  • [Cites] J Surg Oncol. 1993 Sep;54(1):60-3 [8377508.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(5):913-9 [1447034.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):669-73 [16887293.001]
  • [Cites] Urology. 1989 Mar;33(3):185-8 [2919477.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):831-5 [7591890.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] Radiat Res. 1988 Oct;116(1):3-55 [3186929.001]
  • [Cites] J Urol. 2005 Jul;174(1):107-10; discussion 110-1 [15947588.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):191-7 [10368043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):746-8 [12788180.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Oncology. 2000;58(1):75-82 [10644944.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1101-6 [12637477.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):415-24 [8445415.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8):1203-12; discussion 1212-21 [11236311.001]
  • (PMID = 18071867.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Fujisawa H, Takagane H, Shimosegawa K, Sakuma T: [Primary malignant lymphoma of the ureter: a case report]. Hinyokika Kiyo; 2004 Oct;50(10):721-4
Genetic Alliance. consumer health - Primary malignant lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant lymphoma of the ureter: a case report].
  • Computed tomography and retrograde pyelography revealed a soft tissue mass in the middle portion of the right ureter.
  • Urine cytology specimen from the right ureter suggested transitional cell carcinoma.
  • Under the diagnosis of right ureteral cancer, we performed right total nephro-ureterectomy, partial cystectomy.
  • The histopathological examination showed non-Hodgkin lymphoma (large B-cell type) of the ureter.
  • Our diagnosis was Clinical Stage IE of the Ann Arbor Classification.
  • The patient received only the first course of systemic chemotherapy (THP-cop), because he suffered severe thrombocytopenia in the course of the chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Ureteral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15575226.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Gundling F, Zillinger C, Schmidt T, Ingrisch H, Heitland W, Nerlich A, Schepp W: [A 67-year-old patient with diarrhoea and constipation without any pathological findings in virtual colonoscopy]. Z Gastroenterol; 2005 May;43(5):455-9
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] 67-jähriger Patient mit paradoxer Diarrhoe und unauffälliger virtueller Koloskopie.
  • However, conventional video-colonoscopy revealed a subtotal circular malignant stenosis in the region of the right colonic flexure.
  • Staging showed peritoneal carcinosis with infiltration of the right ureter and lymphangiosis carcinomatosa of the pectoral lobe of the left lung.
  • After right hemicolectomy because of metastasised carcinoma of the ascending colon (pT4pN1pM1) we started palliative chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.
  • The risk of misdiagnosis by virtual colonoscopy is clearly increased in patients with subtotal tumour stenosis of the ascending colon.
  • Conventional video-colonoscopy remains the gold standard for the diagnosis of colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Diseases / diagnosis. Colonic Neoplasms / diagnosis. Colonography, Computed Tomographic. Colonoscopy. Constipation / etiology. Diarrhea / etiology. Intestinal Obstruction / diagnosis. Video Recording
  • [MeSH-minor] Aged. Colon / pathology. Diagnostic Errors. Humans. Male. Neoplasm Staging


21. Matsushita M, Kawasaki Y, Okada Y: [Carcinomatous meningitis from urothelial carcinoma of bladder and ureter: case report]. Nihon Hinyokika Gakkai Zasshi; 2004 Nov;95(7):817-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinomatous meningitis from urothelial carcinoma of bladder and ureter: case report].
  • Carcinomatous meningitis from urothelial carcinoma of the bladder and ureter is rare.
  • A 77-year-old man with invasive bladder cancer and right ureter cancer had been treated with 3 courses M-VAC (methotrexate, vinblastine, epirubicin, cisplatin) chemotherapy.
  • After chemotherapy we performed radical cystectomy and right nephroureterectomy (ileal-neobladder) (TCC, G3, pT3, N0, M0).
  • Patient died 6 days after diagnosis of carcinomatous meningitis.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Meningeal Neoplasms / secondary. Meningitis / etiology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Nephrectomy. Ureter / surgery. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624493.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


22. Takagi S, Gohji K, Iwamoto Y, Masuda H, Segawa N, Kiura H, Ueda H, Katsuoka Y: [Ureter cancer of complete double renal pelvis and ureter: a case report]. Hinyokika Kiyo; 2002 Dec;48(12):761-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureter cancer of complete double renal pelvis and ureter: a case report].
  • Intravenous pyelography, computerized tomography and magnetic resonance imaging revealed ureteral tumors of the complete left double renal pelvis and the ureter.
  • An endoscopic examination disclosed a papillary tumor from the left ureteral orifice of the lower pole of the kidney.
  • A transurethral resection of the tumor was done, and the pathological features revealed transitional cell carcinoma (PTa, grade 2).
  • A left nephroureterectomy and a partial cystectomy were also carried out; macroscopic examinations showed a non-papillary tumor on the middle portion of the left ureter originating from the upper pole of the kidney.
  • Adjuvant chemotherapy (M-VAC) was administered but discontinued because of severe side effects.
  • Dispite recurrence with retro-peritoneal lymph node metastasis, the patient is alive and again undergoing M-VAC chemotherapy 22 months after the initial surgery.
  • However, the evaluation of the chemotherapy was "no change".
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis / abnormalities. Neoplasms, Multiple Primary. Ureter / abnormalities. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urologic Surgical Procedures

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613013.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down






Advertisement